About Free Semaglutide Calculator
Our Mission
To democratize access to evidence-based weight loss projection tools, empowering individuals researching GLP-1 medications with accurate, transparent, and clinically-backed information to set realistic expectations for their weight loss journey.
What We Do
The Free Semaglutide Calculator is a free, evidence-based tool that provides personalized weight loss projections for individuals considering or currently using GLP-1 receptor agonist medications such as:
- Wegovy (semaglutide 2.4mg weekly)
- Ozempic (semaglutide 1mg weekly)
- Mounjaro (tirzepatide 15mg weekly)
- Zepbound (tirzepatide 15mg weekly)
- Saxenda (liraglutide 3mg daily)
Our calculator generates week-by-week weight loss timelines, BMI changes, and personalized protein intake recommendations to help users preserve muscle mass during their weight loss journey.
How the Calculator Works
Unlike generic weight loss calculators that use outdated formulas or unsubstantiated estimates, our tool is built on peer-reviewed clinical trial data from the most rigorous studies conducted on GLP-1 medications:
16.9%
Average weight loss
Wegovy (STEP-1)
10.5%
Average weight loss
Ozempic (SUSTAIN)
22.5%
Average weight loss
Mounjaro (SURMOUNT-1)
Calculation Methodology
Our algorithm works as follows:
- Medication Selection: You select the specific GLP-1 medication you are using or considering. Each medication has distinct average weight loss percentages based on clinical trials.
- Weight Loss Percentage Application: The calculator applies the clinically-proven weight loss percentage for your selected medication (e.g., 16.9% for Wegovy, 22.5% for Mounjaro).
- Timeline Generation: We generate a week-by-week projection using a logarithmic curve that mirrors real-world weight loss patterns — faster loss in the first 6 months, gradual tapering toward months 9-12.
- BMI Calculation: We calculate your current BMI and projected BMI at goal weight using the standard formula: (weight in lbs ÷ height² in inches) × 703.
- Protein Recommendation: To help preserve lean muscle mass, we recommend 1 gram of protein per pound of goal body weight, a strategy supported by resistance training research.
Clinical Trial Data Sources
Our projections are based exclusively on data from large-scale, randomized, double-blind, placebo-controlled clinical trials published in leading medical journals:
STEP-1 Trial (Semaglutide 2.4mg — Wegovy)
Study Design: 68-week randomized, double-blind, placebo-controlled trial
Participants: 1,961 adults with obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight-related comorbidity
Results: Average weight loss of 16.9% of body weight (~37 lbs for a 220 lb individual)
Published: New England Journal of Medicine (2021)
SUSTAIN Trials (Semaglutide 1mg — Ozempic)
Study Design: Series of randomized, double-blind trials evaluating semaglutide for type 2 diabetes management
Participants: Adults with type 2 diabetes
Results: Average weight loss of 10.5% at 1mg weekly dose over 68 weeks
Published: The Lancet and Diabetes Care (2017-2019)
SURMOUNT-1 Trial (Tirzepatide 15mg — Mounjaro/Zepbound)
Study Design: 72-week randomized, double-blind, placebo-controlled trial
Participants: 2,539 adults with obesity or overweight with weight-related conditions (excluding diabetes)
Results: Average weight loss of 22.5% at the 15mg maintenance dose (highest efficacy among GLP-1 medications)
Published: New England Journal of Medicine (2022)
SCALE Trial (Liraglutide 3mg — Saxenda)
Study Design: 56-week randomized, double-blind, placebo-controlled trial
Participants: 3,731 adults with obesity or overweight with at least one comorbidity
Results: Average weight loss of 8.0% at the 3mg daily dose
Published: New England Journal of Medicine (2015)
Understanding GLP-1 Medications
What is Semaglutide?
Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist that mimics the natural GLP-1 hormone produced in the gut. It works by:
- Slowing gastric emptying (increasing feelings of fullness)
- Reducing appetite through effects on brain appetite centers
- Improving insulin secretion and reducing glucagon release
- Promoting satiety and reducing food cravings
What is Tirzepatide?
Tirzepatide is a dual GIP/GLP-1 receptor agonist, meaning it activates both glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptors. This dual action produces superior weight loss outcomes compared to semaglutide alone.
Why We Built This Tool
GLP-1 medications have transformed the landscape of obesity treatment, but many individuals struggle to find transparent, evidence-based information about what to expect. We created this calculator to:
- Set Realistic Expectations: Help users understand clinically-backed weight loss timelines rather than relying on anecdotal reports or marketing claims.
- Support Informed Decisions: Provide data-driven projections to facilitate conversations with healthcare providers.
- Promote Muscle Preservation: Highlight the importance of protein intake and strength training to prevent muscle loss during rapid weight reduction.
- Improve Adherence: When users know what to expect week-by-week, they are more likely to stay committed to their medication protocol.
What We Are NOT
It's important to understand the limitations of our tool:
- We are NOT a medical practice. This calculator does not provide medical advice, diagnoses, or treatment recommendations.
- We do NOT prescribe medications. You must obtain GLP-1 medications through a licensed healthcare provider after a thorough medical evaluation.
- We do NOT guarantee results. Individual outcomes vary based on genetics, adherence, diet, exercise, and health conditions.
- We do NOT replace your doctor. Always consult with a healthcare professional before starting, stopping, or modifying any medication.
Our Commitment to Accuracy
We are committed to maintaining the highest standards of scientific accuracy and transparency:
- All weight loss percentages are derived from published, peer-reviewed clinical trials.
- We update our algorithm when new clinical data becomes available.
- We clearly disclose the limitations of our projections (individual variability, trial context, etc.).
- We do not exaggerate results or make unrealistic promises.
Future Development
We are continuously working to improve the calculator by:
- Incorporating new clinical trial data as it is published
- Adding support for additional GLP-1 medications (e.g., oral semaglutide, future dual agonists)
- Expanding our educational content on nutrition, exercise, and muscle preservation strategies
- Developing advanced features such as body composition projections and metabolic rate adjustments
Contact Us
We welcome feedback, questions, and suggestions for improving the Free Semaglutide Calculator. Please reach out to us at:
Email: contact@freesemaglutidecalculator.com